Nonacus

04/06/2024

Hello Edinburgh!

We are excited to announce that we will be one of the sponsors of One Health Genomics Community Meeting, taking place at the University of Edinburgh on Friday 7th June 2024.

Shane Houston will be showcasing GALEAS Tumor, for enhanced comprehensive genomics profiling, and our Cell3 Target Nexome solution for detection of SNVs, INDELS and CNVs.

If you would like to arrange a chat with Shane, reach out to him via email at shane.houston@nonacus.com

04/06/2024

It's the last day of and we are excited about Ieva Miceikaite, PhD from Clinical Research Institute, University of Southern Denmark, Odense, Denmark (project affiliation) and Center for Genomic Medicine, Mass General Hospital, Boston, MA, USA (current affiliation) discussing Comprehensive Non-invasive Prenatal Screening by Deep Trio Exome Sequencing. Watching Nonacus whole exome Sequencing solutions and cfDNA extraction kits making a difference in the world is absolutely outstanding.

30/05/2024

Attending ESHG in Berlin this year? We’d love to see you.👋

Ask us, ‘what’s new at Nonacus?’ and spin our wheel of fortune for a chance to take home some prizes!
Nonacus is your partner in the lab.💚

✅Together we can increase diagnostic yield in rare disease analysis with precise and enhanced whole exome NGS panel design
✅Let’s reduce burden on your team with simple streamlined workflows in hereditary and somatic testing
✅Make sure you call challenging CNVs with a cloud-based turnkey bioinformatics, GALEASTM analysis software – at no additional cost

Join our team at booth #332

08/05/2024

🌊Join us from May 13th to 15th for the 15th International Symposium on Variants in the Genome and dive into the world of genomics in Porto, Portugal!

Meet our incredible team, including Paul Rainey, Global Channel Partner Manager and Andrea Langella Product Manager alongside our Channel Partners Mário Simas and Sonia Martins from Bioportugal.

Don’t miss Andrea Langella’s presentation – ‘Expanding the Nexome: Unveiling disease in non-coding regions with Nexome’ on Monday 13th May at 15:00.

The talk will explore:

✅The limitations of standard WES

✅The importance of non-coding DNA in gene regulation and its role in human disease

✅Real-world examples to showcase how Nexome has identified disease-causing variants in non-coding regions

✅How Nexome maximizes diagnostic yield without inflating sequencing costs, compared to WES

03/05/2024

Our Sales Manager for the DACH region, Sebastian Ziemann, & our Nonacat are attending Tumorgenetische Arbeitstagung (TGA), in this beautiful venue in the city of Volpriehausen, Göttingen.🇩🇪😺

Find Sebastian at stand 11 until Saturday, May 4th! Don’t miss the chance to learn more about our latest GALEAS Tumor NGS solution, including bioinformatics and more! 💚

29/04/2024

Ready for a challenge…? 🤔
Take your shot and figure out the sentence behind the pictogram. Share your guesses down below and let’s crack the code together! 🔍

25/04/2024

Join us in supporting National DNA Day, a global celebration to mark the discovery of the double helix in 1953 and the completion of the human genome project in 2003.

We’ve come a long way in a very short space of time💚

25/04/2024

Guten Tag Germany!
We're pleased to announce our participation in the 36th “Tumorgenetische Arbeitstagung” from May 2-4, 2024, in Volpriehausen, Göttingen.

Our Sales Manager for Germany/Austria, Sebastian Ziemann, will be there to showcase our latest launch: GALEAS Tumor, a clinically validated, genomic profiling solution designed to stratify both prevalent and rare cancers, tailor-made for clinical labs.

Stop by our booth and chat with Sebastian to learn more about our GALEAS products.

24/04/2024

Ciao Italy! 🇮🇹

We are delighted to announce that we will be a premium sponsor at European Association for Cancer Research (EACR) conference in the city of Bergamo from 30 April – 2 May 2024!

Nonacus will be located at stand 5 were our Clinical Specialist Katie Shepherd and our Software Product Manager Product Management, Tim Gilbert will be representing our company. If you're around, don't miss our industry spotlight talk by Tim Gilbert who will be presenting ‘GALEAS: Precision bioinformatics for precision oncology - MSH2 to 1p19q'

See you there!

22/04/2024

It's not too late! 🖥️❗

Excited for tomorrow's webinar with Katie Shepherd, our Clinical Specialist at Nonacus and FrontLine Genomics!

Join us tomorrow, Tuesday 23rd April at 3pm BST/ 4pm CST / 10am EDT, for the second part of the free-to-attend webinar series, Molecular Analysis for Precision Oncology.

Katie Shepherd, Clinical Specialist at Nonacus, will guide us through the GALEAS™ portfolio, designed to support clinical oncology diagnostic and prognostic decisions. She will introduce GALEAS Tumor as a comprehensive genomic profiling tool to stratify prevalent and rare cancers, alongside Cell3™ Target: custom NGS panel design as an aid to understand cancer evolution and patient management.

Missed the first one? Don't worry, catch it on demand. Learn about the latest genomic techniques and how they're revolutionising oncological care.

Register now! > https://bit.ly/4a3lD9T

16/04/2024

Save the date in your calendar!📅

We are excited to announce our collaboration with FrontLine Genomics for their latest webinar series on Molecular Analysis for Precision Oncology.🖥️

Katie Shepherd, Clinical Specialist at Nonacus, will guide us through the GALEAS™ portfolio, designed to support clinical oncology diagnostic and prognostic decisions. She will introduce GALEAS Tumor as a comprehensive genomic profiling tool to stratify prevalent and rare cancers, alongside Cell3™ Target: custom NGS panel design as an aid to understand cancer evolution and patient management.

Don't miss out on the opportunity to stay updated on the clinical applications and future prospects of precision oncology techniques! Register now for this FREE three-part series happening on April 16th, 23rd, & 30th at 3pm BST / 4pm CET / 10am EDT.

Click the link below to register and meet the speakers! Note: Registration automatically enrolls you for all three sessions.

Register now > https://bit.ly/49Maave

03/04/2024

Are you joining us at the European Association of Urology (EAU) congress in Paris from Friday 5th April to Monday 8th April? Swing by booth and come say hello to Andrew Faber and the Nonacus team! Plus, grab your very own tube of hematuria positive M&Ms! 🔴🍫🌕

Hematuria is an indicator of many diseases, including bladder cancer. But with GALEAS Bladder, detection is simple. No more unnecessary cystoscopies – just non-invasive testing. Discover the latest updates at our booth: BUPA reimbursement, the use of GALEAS bladder in the MRD setting, and preliminary surveillance data.

Thrilling times in bladder cancer testing – be part of the change, See you there!

02/04/2024

Introducing GALEAS Tumor! 💚🚨

CGP delivers insights into cancer and informs clinical decisions that improve patient outcomes. However, often the solutions that deliver CGP are expensive, with laborious workflows and outdated content that isn’t clinically relevant or recognized in key guidelines.

GALEAS™ Tumor, a clinically validated comprehensive genomic profiling solution that stratifies both prevalent and rare cancers, has been designed with the clinical lab in mind.


Discover more: https://bit.ly/49j3CUA

28/03/2024

Hematuria, or blood in the urine, can be a frightening symptom for patients. It can be a sign of a variety of conditions, including bladder cancer. Traditional methods for diagnosing bladder cancer can be invasive and uncomfortable, such as cystoscopy. However, there is a new, non-invasive option that is revolutionizing bladder cancer detection: the GALEAS™ Bladder sample to report test.

GALEAS Bladder is a molecular test that can detect bladder cancer using a simple urine sample. The test can identify genetic signatures of cancer cells, in early to late stages of the disease. This allows for earlier detection and treatment, which can lead to better patient outcomes, improvement of patient survival rate and lifestyle.

If you are a healthcare professional, we encourage you to learn more about GALEAS Bladder and how it can benefit you and your patients. 💚👩‍⚕️

26/03/2024

Today is Purple Day, and while green is our favorite colour, we are lighting it up purple! 💜

Did you know that over 626,000 people in the UK are living with epilepsy? Nonacus stand united in raising awareness for all the people suffering with epilepsy. Let’s come together spread knowledge, understanding and support for those living with epilepsy. Together, we can make a difference.

Learn more through the official webpage > https://bit.ly/43wVuyu

25/03/2024

Big news! Our brand-new website is here! 🖥️
Explore with us at Nonacus and discover our user-friendly navigation, expert support and latest updates in cancer diagnostics.

Check out our website today https://bit.ly/3x6Gaw9

22/03/2024

Here’s your Lynch Syndrome fact check. 🔵💚⚪
Learn more how you can do your part as clinician to bridge the gap between testing and diagnosis of Lynch syndrome!
Take 5 minutes to learn more: https://bit.ly/3PtNcSb

22/03/2024

Stop in the name of !

Don’t know enough about Lynch syndrome testing?
Here’s a 5-minute read on how you can help find the 95% of patients that are unaware that they suffer from the disease. Let’s reduce the time between testing and cancer diagnosis together. ⚪💚🔵

Take 5 minutes to learn more:

Supporting Let's Go Dotty: Lynch Syndrome Awareness Day March 22nd, 2024. A one-test NGS solution for Lynch Syndrome screening.